# Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial

Study · id `cardio:ct-nct05496998` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05496998](<https://clinicaltrials.gov/study/NCT05496998>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05496998

Browse, organ or system: Heart  
Browse, condition area: Heart failure; Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 400 participants.

## Technical summary

Registry record NCT05496998. Allocation not applicable; no masking; primary purpose treatment. Start 2023-02-07 (actual); primary completion 2029-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 400 participants (planned count; ClinicalTrials.gov record NCT05496998, source copy `cardio:ctgov-nct05496998-2026-10-30`, retrieved 2026-10-31)
- Started: 2023-02-07 (actual) (ClinicalTrials.gov record NCT05496998, source copy `cardio:ctgov-nct05496998-2026-10-30`, retrieved 2026-10-31)
- Primary completion: 2029-08 (anticipated) (ClinicalTrials.gov record NCT05496998, source copy `cardio:ctgov-nct05496998-2026-10-30`, retrieved 2026-10-31)
- Completion: 2038-12 (anticipated) (ClinicalTrials.gov record NCT05496998, source copy `cardio:ctgov-nct05496998-2026-10-30`, retrieved 2026-10-31)
- Countries: Denmark; France; Germany; Italy; Netherlands; Spain; Switzerland; United Kingdom (ClinicalTrials.gov record NCT05496998, source copy `cardio:ctgov-nct05496998-2026-10-30`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05496998-2026-10-30`, retrieved 2026-10-31)

## The registry's words

- Brief title: Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial
- Acronym: APOLLO-EU
- Condition: Mitral Regurgitation
- Intervention (Device): Medtronic Intrepid™ TMVR TF System
- Lead sponsor: Medtronic Cardiovascular
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry condition terms include this condition: Mitral regurgitation (`cardio:mitral-regurgitation`)
- Registry lists this organization as the lead sponsor: Medtronic (`cardio:medtronic`)

## Provenance

Content hash: 531662b66cb2cbc9e83d0d89b47b9a937e5d5bda14feb053cccd90964d4fead1
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
